Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer

pharmafile | April 1, 2019 | News story | Research and Development, Sales and Marketing |  Cancer, Roche, breast cancer, pharma, tecentriq 

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of advanced triple-negative breast cancer (TNBC).

The findings showed that the combination of ipatasertib, Tecentriq (atezolizumab) and chemotherapy (paclitaxel or nab-paclitaxel (Abraxane [paclitaxel albumin-bound particles for injectable suspension]) delivered an objective response rate (ORR) of 73% in the study’s 26 participants, regardless of tumour biomarker status.

“We are enthusiastic about the potential of this combination in triple-negative breast cancer, an aggressive type of breast cancer,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “These early results support the contribution of ipatasertib to our combination treatment approach in TNBC and reinforce our vision to develop medicines that may benefit patients with this challenging disease.”

Roche confirmed that a multi-centre Phase 3 study into the efficacy of Tecentriq, ipatasertib, and paclitaxel in the treatment of locally advanced/metastatic triple-negative breast cancer will launch later this year.

Matt Fellows